Data for BRCA1/2 germline test results were available for 168 patients (88.4%); 5 patients refused testing; 3 patients did not fulfill the inclusion criteria for cost coverage of their insurance companies due to advanced age; 8 patients’ insurance companies refused testing due to other reasons; and 6 patients’ tests were not conducted, as a BRCA1/2 mutation/HRD was shown to be present in the tumor. This evidence concerns the gene BRCA1 and neoplasm.